2. Search Result
Search Result
Results for "

MOR partial agonists/D3R antagonisists

" in MedChemExpress (MCE) Product Catalog:

6237

Inhibitors & Agonists

3

Screening Libraries

25

Fluorescent Dye

62

Biochemical Assay Reagents

763

Peptides

51

Inhibitory Antibodies

470

Natural
Products

524

Isotope-Labeled Compounds

2

Antibodies

26

Click Chemistry

65

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117059
    SK609 hydrochloride

    		Dopamine Receptor Neurological Disease
    SK609 hydrochloride is a dopamine D3 receptor (D3R) selective agonist with an EC50 of 1109 nM. SK609 hydrochloride has the potential for parkinson research .
    SK609 hydrochloride
  • HY-116820
    OS-3-106

    		Dopamine Receptor Neurological Disease
    OS-3-106 is a potent, BBB-penetrated and selective dopamine D3 receptor (D3R) agonist. OS-3-106 binds with high affinity (Ki = 0.2 nM) at the D3R. OS-3-106 can be used for psychoactivator addiction research .
    OS-3-106
  • HY-155707
    MOR agonist-3

    		Dopamine Receptor Inflammation/Immunology
    MOR agonist-3 (Compound 84) is a D3R/MOR antagonist/partial agonist a(Ki 382 nM and 55.2 nM respectively). MOR agonist-3 has the potential to produce analgesic effects through MOR (μ-opioid receptor) (HY-149337) partial agonists and to reduce opioid abuse through D3R antagonists. MOR agonist-3 can be used in the treatment of inflammation and neuropathic pain research .
    MOR agonist-3
  • HY-149387
    D3R/MOR antagonist 2

    		Dopamine Receptor Opioid Receptor Inflammation/Immunology
    D3R/MOR antagonist 2 (Compound 121) is a D3R/MOR antagonist (Ki: 361 nM and 85.2 nM respectively). D3R/MOR antagonist 2 has the potential to produce analgesic effects through MOR partial agonism, reduce opioid-misuse liability via D3R antagonism .
    D3R/MOR antagonist 2
  • HY-149386
    D3R/MOR antagonist 1

    		Dopamine Receptor Opioid Receptor Inflammation/Immunology
    D3R/MOR antagonist 1 (Compound 114) is a D3R/MOR antagonist (Ki: 46.5 nM and 691 nM respectively). D3R/MOR antagonist 1 has the potential to produce analgesic effects through MOR partial agonism, reduce opioid-misuse liability via D3R antagonism .
    D3R/MOR antagonist 1
  • HY-149337
    D3R ligand 1

    		Dopamine Receptor Neurological Disease
    D3R ligand 1 (compound 23b) is a potent and selective ligand of dopamine receptor D3R (Ki=66 nM), containing a THPB template. D3R ligand 1 is also an antagonist for both G-protein- and β-arrestin-based signaling .
    D3R ligand 1
  • HY-155706
    MOR agonist-2

    		Opioid Receptor Dopamine Receptor Inflammation/Immunology
    MOR agonist-2 (compound 46) is a antagonist of D3R and agonist of MOR (Ki: 7.26 nM and 564 nM, respectively). MOR agonist-2 has the potential to produce analgesic effects through MOR partial agonism. MOR agonist-2 reduces opioid-misuse liability via D3R antagonism .
    MOR agonist-2
  • HY-129890
    7-Hydroxy-PIPAT

    		Dopamine Receptor Neurological Disease
    7-Hydroxy-PIPAT (compound 2) is a D3R agonist. 7-Hydroxy-PIPAT is a high affinity to D3 dopamine receptor with Ki value of 0.99 nM .
    7-Hydroxy-PIPAT
  • HY-156239
    Dopamine D3 receptor ligand-5

    		Dopamine Receptor 5-HT Receptor Neurological Disease
    Dopamine D3 receptor ligand-5 (13a), a Cariprazine (HY-14763) analogue, is a dopamine D3 receptor ligand, with Ki values of 2.85 nM and 0.14 nM for D2R and D3R, respectively .
    Dopamine D3 receptor ligand-5
  • HY-153471
    MOR agonist-1

    		Opioid Receptor Infection Inflammation/Immunology
    MOR agonist-1 is a MOR (μ-opioid receptor) agonist. MOR agonist-1 has good analgesic effect. MOR agonist-1 can be used for the research of pain and pain-related disorders .
    MOR agonist-1
  • HY-176287
    ARN25657

    		Dopamine Receptor GSK-3 PKA P-glycoprotein Neurological Disease
    ARN25657 is a dual-acting D3R/GSK-3β modulator. ARN25657 has both partial D3R agonist activity (EC50 = 15.2 nM, Ki =1.5 nM) and potent GSK-3β inhibitor activity (IC50 = 19.3 nM). ARN25657 exhibits excellent GSK-3β selectivity over FYN, PKA, and CDK5/p35. ARN25657 inhibits P-glycoprotein (P-gP)-mediated acetoxymethyl calcein efflux and improves in vitro ADME properties while maintaining a balanced dual-target profile. ARN25657 is useful for studying bipolar disorder and related neuropsychiatric disorders .
    ARN25657
  • HY-111280
    ST 198

    		Dopamine Receptor Neurological Disease
    ST 198 is an orally active D3R antagonist. ST 198 can block the expression of nicotine-induced CPP at doses selective for D3R. ST 198 can be used for the research of neurological disease .
    ST 198
  • HY-124583
    PF-4363467

    		Dopamine Receptor Neurological Disease
    PF-4363467, a dopamine D3/D2 receptor antagonist, attenuates opioid drug-seeking behavior without concomitant D2 side effects. PF-4363467 exhibits Ki values of 3.1 nM and 692 nM for D3R and D2R .
    PF-4363467
  • HY-136390
    ML417
    1 Publications Verification

    		 Dopamine Receptor Neurological Disease
    ML417 is a selective and brain penetrant D3 dopamine receptor (D3R) agonist, with an EC50 of 38 nM. ML417 potently promotes D3R-mediated β-arrestin translocation, G protein mediated signaling, and pERK phosphorylation with minimal effects on other GPCR-mediated signaling. ML417 exhibits neuroprotection against toxin-induced neurodegeneration of dopaminergic neurons .
    ML417
  • HY-175505
    Dopamine D3 receptor antagonist-3

    		Dopamine Receptor Neurological Disease
    Dopamine D3 receptor antagonist-3 is a D3 dopamine receptor (D3R)-selective positive allosteric modulator (PAM)-antagonist that can cross the blood-brain barrier. Dopamine D3 receptor antagonist-3 exhibits antagonist activity in the D3R-mediated β-arrestin recruitment assay with an IC50 and a Kb of 2.5 μM and 0.49 μM. amine D3 receptor antagonist-3 is also an antagonist in the D3R-mediated Go-BRET assay with an IC50 of 0.34 μM. Dopamine D3 receptor antagonist-3 can be used for the study of neuropsychiatric disorders, including substance use disorder .
    Dopamine D3 receptor antagonist-3
  • HY-175504
    MLS6357

    		Dopamine Receptor PERK Neurological Disease
    MLS6357 is a D3 dopamine receptor (D3R)-selective positive allosteric modulator (PAM)-antagonist. MLS6357 exhibits antagonist activity in the D3R-mediated and the BRET-based β-arrestin recruitment assay with IC50s of 13 and 14 μM, and no activity for other DAR subtypes (D1R/D2R/D4R/D5R) (IC50 > 100 μM). MLS6357 is also an antagonist in the D3R-mediated Go-BRET assay with an IC50 of 17 μM. MLS6357 can be used for the study of neuropsychiatric disorders, including substance use disorder .
    MLS6357
  • HY-N15180
    Corynantheidine

    (-)-Corynantheidine

    		 Opioid Receptor Neurological Disease
    Corynantheidine ((-)-Corynantheidine) is a mu-opioid receptor (MOR) partial agonist that shows MOR-dependent analgesic effects in mice .
    Corynantheidine
  • HY-10847B
    SB-277011 hydrochloride
    1 Publications Verification

    SB-277011A hydrochloride

    		 Dopamine Receptor 5-HT Receptor Neurological Disease
    SB-277011 hydrochloride (SB-277011A hydrochloride) is a potent, selective, orally bioavailable and brain penetrate dopamine D3 receptor (D3R) antagonist with Ki values of 10.7 nM and 11.2 nM at rodent and human D3R, respectively. SB-277011 hydrochloride displays 80- to 100-fold selectivity over other dopamine receptors with pKis of 8.0, 6.0, <5.2, and 5.9 for D3, D2, 5-HT1B, and 5-HT1D receptors, respectively .
    SB-277011 hydrochloride
  • HY-119768
    (±)-BAK2-66

    		Dopamine Receptor Neurological Disease
    (±)-BAK2-66 is a selectivity dopamine D3 receptor antagonist with theKi values of 1nM and 960 nM for D3R and D2R, respectively. (±)-BAK2-66 can be used for study in animal models of addiction .
    (±)-BAK2-66
  • HY-109743
    BP14979

    		Dopamine Receptor Neurological Disease
    BP14979 is a dopamine D3 receptor agonist with activity in the study of neurological diseases. BP14979 can be used to develop ligands with higher selectivity and affinity for D3 receptors. The structural characteristics of BP14979 make it potential in modulating the efficacy of D3 receptors. The design of BP14979 is based on the difference in efficacy with D3R selective antagonists, providing opportunities for optimizing new drug development .
    BP14979
  • HY-161812
    MOR agonist-4

    		Opioid Receptor Others
    MOR agonist-4 (2d) is a G protein signaling-biased Kappa opioid receptor (KOR) agonist with an EC50 value of 11 nM. MOR agonist-4 contains an electron withdrawing CF3 group and a bias factor of 38 based on triazole. MOR agonist-4 is used in the research of pruritis and analgesia .
    MOR agonist-4
  • HY-109167
    Aramisulpride

    (R)-Amisulpride; (R)-Esamisulpride; (R)-DAN 2163

    		 Dopamine Receptor 5-HT Receptor Neurological Disease
    Aramisulpride (R-(+)-Amisulpride) is the R-isomer of Amisulpride (HY-14545). Aramisulpride is a 5-HT7 receptor antagonist with a Ki value of 22 nM. Aramisulpride is a D2/D3 receptor antagonist with a Ki value of 140 nM for D2R and a Ki value of 13.9 nM for D3R. Aramisulpride can be used in psychiatric research .
    Aramisulpride
  • HY-172979
    DH-1-106

    		Opioid Receptor Neurological Disease
    DH-1-106 is a MOR partial agonist. DH-1-106 can be used in the study of analgesia .
    DH-1-106
  • HY-P991598
    MOR-106

    MOR12743; MOR03207

    		 Interleukin Related NF-κB Inflammation/Immunology
    MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis .
    MOR-106
  • HY-126068
    Esamisulpride

    (S)-Amisulpride; (S)-Aramisulpride; (S)-DAN 2163

    		 Dopamine Receptor 5-HT Receptor Neurological Disease
    Esamisulpride ((S)-Amisulpride) is the S-isomer of Amisulpride (HY-14545). Esamisulpride is a potent dopamine D2/D3 receptor antagonist with Ki values of 4.43 nM for D2R and 0.72 nM for D3R. Esamisulpride is a 5-HT7 receptor antagonist with a Ki of 900 nM. Esamisulpride can be used in the research of schizophrenia and depression [3].
    Esamisulpride
  • HY-103418
    Dopamine D2 receptor agonist-3

    		Dopamine Receptor Neurological Disease
    Dopamine D2 receptor agonist-3 (compound 3) is a selective D2 receptor partial agonist and Dopamine D3 receptor antagonist (with pEC50 of 8.3 and <5.5 respectively) .
    Dopamine D2 receptor agonist-3
  • HY-P99616
    Felzartamab

    MOR-202

    		 CD38 Cancer
    Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research .
    Felzartamab
  • HY-P991591
    MOR101

    		Integrin Inflammation/Immunology
    MOR101 is a humanized monoclonal antibody inhibitor targeting ICAM-1/CD54. MOR101 can be used to study acute and chronic inflammation, such as burns .
    MOR101
  • HY-170437
    MOR modulator-1

    		Opioid Receptor Neurological Disease
    MOR modulator-1 (compound 6) is a potent and selective μ opioid receptor (MOR) modulator. MOR modulator-1 exhibits improved opioid receptor selectivity, enhanced in vivo antagonistic effect, and overall fewer withdrawal symptoms compared to NAT (6α-configuration). MOR modulator-1 links with carboxamido linker μ, δ, γ with Kis of 0.25, 41.1, 1.30 nM, respectively[1]
    MOR modulator-1
  • HY-P10203
    μ/κ/δ opioid receptor agonist 1

    		Opioid Receptor Inflammation/Immunology
    μ/κ/δ opioid receptor agonist 1 is a μ opioid receptor (MOR), κ opioid receptor (KOR), and δ opioid receptor (DOR) agonist. μ/κ/δ opioid receptor agonist 1 produces a strong and long-lasting analgesic effect through peripheral MOR and KOR in the tail-flick test .
    μ/κ/δ opioid receptor agonist 1
  • HY-P1433
    [Pro3]-GIP (Rat)

    		Insulin Receptor Metabolic Disease
    [Pro3]-GIP (Rat) is a selective GIP receptor partial agonist with a Ki of 13 nM. [Pro3]-GIP (Rat) can be used in diabetes research .
    [Pro3]-GIP (Rat)
  • HY-106206
    AL-6598

    		Prostaglandin Receptor Cardiovascular Disease
    AL-6598 is a partial agonist of the DP and EP prostaglandin receptors. AL-6598 reduces intraocular pressure and is used in glaucoma research .
    AL-6598
  • HY-107680
    3-Pyr-Cytisine

    3-Pyr-Cyt

    		 nAChR Neurological Disease
    3-Pyr-Cytisine (3-Pyr-Cyt) is a cytisine derivative. 3-Pyr-Cytisine is a very weak α4β2 nAChR partial agonist that has been studied as an antidepressant .
    3-Pyr-Cytisine
  • HY-U00090
    N-Methylmoranoline

    MOR 14; N-Methyl-1-deoxynojirimycin; N-MethylMORanolin

    		 Glycosidase Metabolic Disease
    N-Methylmoranoline (MOR 14) is an α-glucosidase inhibitor.
    N-Methylmoranoline
  • HY-172637
    Phenethyl 4-ANPP

    		Opioid Receptor Neurological Disease
    Phenethyl 4-ANPP is a MOR (μ-opioid receptor) agonist. Phenethyl 4-ANPP is an analytical reference standard that is structurally similar to known opioids .
    Phenethyl 4-ANPP
  • HY-D2285
    MOR-CES2

    		Fluorescent Dye Cancer
    MOR-CES2 is a near-infrared fluorescent probe (Ex= 630 nm, Em=735 nm) capable of identifying cancer cells and tissues, as well as exhibiting a sensitive response to inflammation. MOR-CES2 holds potential as an efficient imaging tool in assisting surgical resection of CES2-related tumors .
    MOR-CES2
  • HY-19082
    Y-23684

    		GABA Receptor Neurological Disease
    Y-23684 is a partial agonist of benzodiazepine receptor (BZR) with anticonvulsant and anxiolytic activities. Y-23684 can be used in the research of treatment of anxiety disorders .
    Y-23684
  • HY-123813
    CCX-777

    		Arrestin Cancer
    CCX-777 is a partial agonist of β-arrestin-2 recruitment to ACKR3 (atypical chemokine receptor 3) .
    CCX-777
  • HY-10019
    Varenicline

    CP 526555

    		 nAChR Neurological Disease Inflammation/Immunology Cancer
    Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation [3] .
    Varenicline
  • HY-10020
    Varenicline Hydrochloride

    CP 526555 hydrochloride

    		 nAChR Neurological Disease Inflammation/Immunology Cancer
    Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation [3] .
    Varenicline Hydrochloride
  • HY-10019A
    Varenicline dihydrochloride

    CP 526555 dihydrochloride

    		 nAChR Neurological Disease Inflammation/Immunology Cancer
    Varenicline (CP 526555-18) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation [3] .
    Varenicline dihydrochloride
  • HY-10021
    Varenicline Tartrate

    CP 526555-18

    		 nAChR ERK p38 MAPK Others Neurological Disease Cancer
    Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation [3] .
    Varenicline Tartrate
  • HY-W725190A
    Piperidylthiambutene

    		Opioid Receptor Neurological Disease
    Piperidylthiambutene is a potent µ-opioid receptor (MOR) agonist with a Ki of 2.75 nM. Piperidylthiambutene exhibits analgesic and antitussive properties and can be utilized in relevant research .
    Piperidylthiambutene
  • HY-105627A
    Profadol hydrochloride

    CI-572 hydrochloride

    		 GABA Receptor iGluR Cardiovascular Disease
    Profadol (CI-572) hydrochloride is a potent analgesic agent. Profadol is a µ-opioid receptor (MOR) agonist. Profadol hydrochloride activates the γ-aminobutyric acid (GABA) receptors and inhibits the N-methyl-D-aspartate (NMDA) receptor. Profadol increases the mRNA and protein expression of MOR .
    Profadol hydrochloride
  • HY-110142
    Thermopsidine

    CC4

    		 nAChR Neurological Disease
    Thermopsidine (CC4) is a selective partial agonist at α4β2/α6β2 nAChR with EC50 values of 2.2 μM target α4β2 .
    Thermopsidine
  • HY-10021R
    Varenicline Tartrate (Standard)

    CP 526555-18 (Standard)

    		 Reference Standards nAChR ERK p38 MAPK Others Neurological Disease
    Varenicline (Tartrate) (Standard) is the analytical standard of Varenicline (Tartrate). This product is intended for research and analytical applications. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation [3] .
    Varenicline Tartrate (Standard)
  • HY-10019R
    Varenicline (Standard)

    CP 526555 (Standard)

    		 Reference Standards nAChR Neurological Disease Inflammation/Immunology Cancer
    Varenicline (Standard) is the analytical standard of Varenicline. This product is intended for research and analytical applications. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation [3] .
    Varenicline (Standard)
  • HY-10019AR
    Varenicline dihydrochloride (Standard)

    CP 526555 dihydrochloride (Standard)

    		 Reference Standards nAChR Neurological Disease Inflammation/Immunology Cancer
    Varenicline (dihydrochloride) (Standard) is the analytical standard of Varenicline (dihydrochloride). This product is intended for research and analytical applications. Varenicline (CP 526555-18) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation [3] .
    Varenicline dihydrochloride (Standard)
  • HY-10020R
    Varenicline Hydrochloride (Standard)

    CP 526555 hydrochloride (Standard)

    		 Reference Standards nAChR Neurological Disease Inflammation/Immunology Cancer
    Varenicline (Hydrochloride) (Standard) is the analytical standard of Varenicline (Hydrochloride). This product is intended for research and analytical applications. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation [3] .
    Varenicline Hydrochloride (Standard)
  • HY-10019S1
    Varenicline-15N,13C,d2

    CP 526555-15N,13C,d2

    		 nAChR Isotope-Labeled Compounds Neurological Disease Inflammation/Immunology Cancer
    Varenicline- 15N, 13C,d2 is 15N and deuterated labeled Varenicline (HY-10019). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50=250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation [3] .
    Varenicline-15N,13C,d2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: